- Affirmative Recovery
- Alternative Dispute Resolution
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
September 22, 2020New York Law Journal Recognizes Hollis Salzman as a Trailblazer
-
September 18, 2020Teresa Fariss Mcclain Recognized as Woman worth Watching by Profiles in Diversity Journal
-
September 17, 2020Robins Kaplan LLP Files New Lawsuit Against Delbarton School and the Order of St. Benedict of New Jersey on behalf of Survivors of Child Sex Abuse
-
September 29, 2020The Profound Importance of Authentic Leadership, Especially During a Crisis
-
September 29, 2020Turnaround Management Association (TMA) IMPACT 2020 Global Conference
-
September 30, 2020From Contract to Courtroom: Lessons Learned in Contract Litigation and Trials
-
Summer 2020Following a Varied Legal Career, Judge Jonathan Kobes Begins on the Eighth Circuit
-
September 22, 2020Herbal Patent Protection
-
August 24, 2020Hot off the Presses: California Further Regulates Out-of-State Adjusters in the Wake of Record-Breaking Catastrophic Losses
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generics Need Sword, Shield For 'Exceptional' Patent Case
Strategies for generic drug companies to avoid paying exceptional-case attorney fees and costs in patent litigation with brand holder.
September 18, 2014
Generic drug companies marketing in the U.S. have particularly rough going these days. The year 2013 saw substantial new Generic Drug User Fee Amendments "user fees" levied on generics for access to the U.S.Food and Drug Administration. The same year brought the U.S. Supreme Court’s Actavis decision: Now the Federal Trade Commission can sue generics for structuring pharma litigation settlements such that the generic company receives something of value from the brand.
All Content © 2003‐2014, Portfolio Media, Inc.
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
Law360
READ FULL ARTICLE Related Professionals
Jeffrey Alan Hovden
Partner
Related Publications
September 22, 2020
Herbal Patent Protection
Shui Li - 闻宁阁 American Intellectual Property
August 26, 2020
INSIGHT: Avoiding Trade Secret Claims After Seeing a Competitor’s Crown Jewels
Jake Holdreith, David Prange, Emily Tremblay - Bloomberg Law
August 3, 2020
Request for Amici: Tell SCOTUS to Incentivize Original Fictional Characters through Copyright
Patrick Arenz - IPWatchdog
Summer 2020
ANDA Approvals
GENERICally Speaking Summer 2020
Summer 2020
ANDA Litigation Settlements
GENERICally Speaking Summer 2020
Related News
September 15, 2020
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.